Document is current
Any future updates will be listed below
-
Authors
Gonzalez-Ortiz, Fernando
Kac, Przemysław R.
Brum, Wagner S.
Zetterberg, Henrik
Blennow, Kaj
Karikari, Thomas K. http://orcid.org/0000-0003-1422-4358
-
Funding
Funding for this research was provided by:
Alzheimer's Association
National Institute on Aging
BrightFocus Foundation
University of Gothenburg
- License Information
-
More Information
Article History
Received: 31 October 2022
Accepted: 15 February 2023
First Online: 16 March 2023
Declarations
:
: Not applicable.
: Not applicable.
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant or at advisory boards for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers. HZ and KB are co-founders of Brain Biomarker Solutions in Gothenburg AB, which is a part of the GU Ventures Incubator Program (outside submitted work). The other authors declare no competing interest.
